-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Moderna announced that the Phase 2/3 clinical trial of the candidate vaccine mRNA-1345 has completed the first patient administration for the prevention of respiratory syncytial virus (RSV) infection
RSV is a common respiratory virus that generally causes cold-like symptoms.
mRNA-1345 is an mRNA vaccine encoding the F glycoprotein before stable fusion of the virus.
In a phase 1 clinical trial conducted in young adults, one month after subjects received a single dose of vaccine (100 μg), the geometric mean titers of neutralizing antibodies against RSV-A or RAV-B increased by 21 times and respectively compared with baseline.
In addition, Moderna's respiratory virus research and development project also includes the development of mRNA vaccines against other viruses such as seasonal influenza
Reference materials:
[1] Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine.